Tagged with Vaccines,

Coronavirus Top global pharma executives involved in the development of COVID-19 vaccines have stated their commitment to not rushing the release of any potential vaccine without it passing through the full clinical trial process and proving to be safe and effective. Albert Bourla of Pfizer and Kenneth Frazier of Merck (MSD…

Canada The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt end to Canada’s participation in CanSino Biologics’ clinical trials the country’s first medical cannabis clinical trial, and Innovative Medicines Canada’s top priorities.   Canada signs deals for J&J, Novavax COVID vaccines https://pharmaphorum.com/news/canada-signs-deals-for-jj-novavax-COVID-vaccines/ Under the…

Sanofi With former head David Loew moving to the CEO position at Ipsen, Sanofi appointed French national Thomas Triomphe as the new head of its vaccines business unit, Sanofi Pasteur, on June 15th 2020.    Under the watch of CEO Paul Hudson, appointed at the end of 2019, Sanofi has initiated…

GSK GSK, the world’s largest manufacturer of vaccines, has pursued a different strategy to that of its contemporaries in the effort to develop a safe, effective, and mass-producible COVID-19 vaccine. PharmaBoardroom recently spoke to Emmanuel Hanon, GSK’s senior VP for vaccines R&D, to get his take on the company’s unique role…

Brazil In the race to develop the world’s first COVID-19 vaccine, Brazil – now one of the world’s worst-affected countries – is becoming an attractive clinical trial destination for biopharma companies that heading into phase III trials. Chinese firm Sinovac recently received regulatory approval to test its vaccine candidate in Brazil…

India Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with India-developed vaccine candidates moving swiftly toward Phase I and II human trials thanks to international partnerships and financial backing.    The Indian companies currently at the forefront of COVID-19 vaccine development are…

Vaccines Jeremy Farrar, director of the Wellcome Trust, spoke to Financial Times correspondent Vanessa Kortekaas on 25 June 2020 about the global race to develop a COVID-19 vaccine. He emphasized the importance of prioritising access to at-risk populations, supply chain scale issues that must be considered, why there is no future…

France French pharma giant Sanofi is pivoting its focus to invest more heavily in vaccines with a plan to invest USD 679 million in vaccine manufacturing operations in the next two years. This announcement came shortly after news of further rounds of layoffs of research staff working on cardiovascular diseases and…

Belgium In an exclusive interview, GSK’s Senior VP for Vaccines R&D Dr Emmanuel Hanon discusses how the sharing of GSK’s adjuvant technology with a wealth of scientific institutions and companies globally can contribute to the rapid development of a safe and effective COVID-19 vaccine. Dr Hanon outlines the challenges inherent in…

Coronavirus Against the backdrop of an unprecedented collaborative global push to develop a COVID-19 vaccine, pharma industry executives and patient advocacy representatives at the BIO 2020 digital conference discussed the progress made towards developing a HIV vaccine and what developers of potential COVID-19 treatments and vaccines can learn from it.  …

China Chinese biotech CanSinoBIO is racing against the clock to have a COVID-19 vaccine ready to begin production in early 2021. The firm’s senior VP of International Business Pierre Morgon reflects on CanSinoBIO’s progress thus far and a timeline of what we can realistically expect if and when Chinese authorities give…

Vaccines Vaccines are back on top of the pharma priority list as companies race against the clock to develop the first effective COVID-19 vaccine. Below we present the top 10 pharma companies producing vaccines globally, based on revenues from 2017 and projected revenues from 2024. GSK leads the pack with over…